Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,142.5
-18.1 (-0.57%)

 

  • STI Straits Times Index
    3,142.5
    -18.1 (-0.57%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,566.5
    -7.6 (-0.48%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,566.7
    -219.5 (-0.82%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,941.6
    -12.8 (-0.43%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,625.4
    76.5 (0.34%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,244.9
    19.4 (0.31%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,080.6
    -8.2 (-0.39%)
    Index delayed 20 minutes
  • XAO XAO
    6,778.2
    -0.4 (-0.01%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 680.5M
  • Value: 822.2M
  • Rise: 138
  • Fall: 166
  • Unch: 527

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
SunMoonFood^0.067-0.002
Rex Intl0.095-
Sembcorp Marine1.390+0.040
Golden Agri-Res0.210-
Mapletree Log Tr1.700+0.040
TEE Intl0.047+0.003
Capital World0.011-0.001
Singapore-eDev0.049-0.001
SingTel3.240-0.020
AEM1.390+0.060

World Indices

World Indices
Name Last Change
Nasdaq 8,104.3 -58.7
HSI 26,566.7 -219.5
HSCEI 10,451.7 -75.2
Jakarta 6,244.7 +19.2
Nikkei 225 22,625.4 +76.5
SSE Comp 2,941.6 -12.8
Shanghai A 3,081.8 -13.4
Shanghai B 264.3 -1.3
PSE Comp 0.0
KOSPI 2,080.6 -8.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CLOVIS ONCOLOGY INC CLOVIS ONCOLOGY
Updated on 22 Oct 2019 (End of trading day)
Last (USD): 3.440 Change: - High: 3.600 Remarks: -
Change (%): - Low: 3.380
Open 3.500 Yesterday's Close 3.44
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 2,498,564 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -6.73306 Trailing EPS (USD) e -7.24469 NAV (USD) b -0.5485
PE a - Trailing PE f - Price / NAV b -6.2716
Dividend (USD) d - Cash In Hand (USD) g 1.9871 Issued & Paid-up Shares c 54,657,000
Dividend Yield (%) d - Price / Cash In Hand g 1.731 Treasury Shares h -
Beta - 75 Daysi -0.332 R-Squared - 75 Days(%)i 0.02 Market Cap (M) 188.020
Beta - 500 Daysi 0.114 R-Squared - 500 Days (%)i 0.06 Enterprise Value (M) 485.041
Piotroski F Score 0 Exchange Code CLVS Par Value ( $ ) n.a.
52 Weeks Volatility (%) 91.41 Free Float (%) 95.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 05 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CLOVIS ONCOLOGY INC NASDAQ 188.020 - - -6.2716 -
Industry Biotechnology NASDAQ 2,235.089 137.408 104.802 5.2638 0.782
Local Peer AMGEN INC NASDAQ 122,836.756 14.634 15.436 11.3801 2.706
Local Peer GILEAD SCIENCES INC NASDAQ 83,408.397 15.290 14.006 3.6880 3.504
Local Peer CELGENE CORP NASDAQ 74,205.183 18.340 14.078 7.3829 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 49,109.107 23.425 22.171 9.6863 -
Local Peer ILLUMINA INC NASDAQ 45,430.350 55.000 48.433 10.4871 -
Local Peer BIOGEN INC NASDAQ 51,990.076 11.734 9.820 4.0138 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 33,112.267 13.546 16.002 3.3941 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 22,261.257 286.870 16.693 2.1903 -
Local Peer SEATTLE GENETICS INC NASDAQ 16,656.646 - - 13.0966 -
Local Peer INCYTE CORPORATION NASDAQ 16,884.910 154.210 55.203 7.5138 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 12,155.029 - - 4.1051 -
Local Peer EXACT SCIENCES CORP NASDAQ 11,504.742 - - 15.0285 -
Other Local Peers GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NATERA INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), XENCOR INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), OPKO HEALTH INC (NASDAQ), VERACYTE INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), FATE THERAPEUTICS (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), INTREXON CORP (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), VANDA PHARMACE INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), NEXTCURE INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), CORTEXYME INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), MACROGENICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), TRANSLATE BIO INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), IMMUNOGEN INC (NASDAQ), XBIOTECH INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), DERMIRA INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), PERSONALIS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MEDICINOVA INC (NASDAQ), AGENUS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), PDL BIOPHARMA INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), MANNKIND CORPORATION (NASDAQ), SERES THERAPEUTICS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), CHIASMA INC (NASDAQ), KAMADA (NASDAQ), ATHERSYS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), AFFIMED N V (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), IMV INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), AXCELLA HEALTH INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SESEN BIO INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), NANTKWEST INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), VBI VACCINES INC CDA (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), CHIMERIX INC (NASDAQ), TREVENA INC (NASDAQ), VERASTEM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), VACCINEX INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), CURIS INC (NASDAQ), OTONOMY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), INFLARX N V (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ORGENESIS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), VERMILLION INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), IVERIC BIO INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), SAVARA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BIOCARDIA INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OCUGEN INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TOCAGEN INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ATYR PHARMA INC (NASDAQ), VAXART INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), ADVAXIS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), TROVAGENE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), OPGEN INC (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), NEURALSTEM INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ)
Global Peer CSL ASX 113,805.144 42.418 42.418 15.2082 1.058
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer AGILENT TECHNOLOGIES INC NYSE 23,114.165 73.146 21.562 4.8692 0.820
Global Peer SINO BIOPHARM HKEx 135,326.830 12.630 13.034 3.9757 0.680
Global Peer WUXI BIO HKEx 98,614.421 132.030 103.217 10.1512 -
Global Peer BEIGENE HKEx 62,917.862 - - 5.1828 -
Global Peer 3SBIO HKEx 34,831.312 23.025 28.025 3.4330 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer GENSCRIPT BIO HKEx 32,603.025 196.078 - 9.1941 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,800.332 44.662 - 2.8318 -
Other Global Peers FRONTAGE (HKEx), POLYNOVO LIMITED (ASX), VIVA BIOTECH (HKEx), HAOHAI BIOTEC (HKEx), AVITA MEDICAL LTD (ASX), MESOBLAST LTD (ASX), MYOVANT SCIENCES LTD (NYSE), ASCLETIS-B (HKEx), CKLIFE SCIENCES (HKEx), ESSEX BIO-TECH (HKEx), KADMON HLDGS INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), NEXT SCIENCE LTD (ASX), LEE'S PHARM (HKEx), STARPHARMA HOLDINGS LIMITED (ASX), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), PFENEX INC (NYSE American), RESAPP HEALTH LIMITED (ASX), NEUREN PHARMACEUTICALS LTD (ASX), BBI LIFE SCI (HKEx), ENZO BIOCHEM INC (NYSE), UNI-BIO GROUP (HKEx), NANOVIRICIDES INC (NYSE American), LINEAGE CELL THERAPEUTICS INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PHYLOGICA LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), CEL-SCI CORP (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), PORT (SET), SYNTHETIC BIOLOGICS INC (NYSE American), CT ENTERPRISE (HKEx), ONCOSIL MEDICAL LIMITED (ASX), IMUGENE LIMITED (ASX), ORTHOCELL LIMITED (ASX), IBIO INC (NYSE American), ARMATA PHARMACEUTICALS INC (NYSE American), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), REGENT PACIFIC (HKEx), INDIA GLOBALIZATION CAPITAL INC (NYSE American), BIOTRON (ASX), ACTINOGEN MEDICAL LTD (ASX), RHINOMED LIMITED (ASX), BIOSINO BIO-TEC (HKEx), EXTRAWELL PHAR (HKEx), ORAGENICS INC (NYSE American), KAZIA THERAPEUTICS LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), GENETIC TECHNOLOGIES (ASX), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), ADALTA LTD (ASX), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), CELLMID LIMITED (ASX), BENITEC BIOPHARMA LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), HAO WEN HLDGS (HKEx), MEGASUN (Bursa), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), MGRC (Bursa), ANATARA LIFESCIENCES LTD (ASX), AIM IMMUNOTECH INC (NYSE American), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), QT Vascular (SGX), CCP TECHNOLOGIES LTD (ASX), NANOLLOSE LTD (ASX), NOVITA HEALTHCARE LTD (ASX), BPH ENERGY LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.240
+7.50 %
10 Days -+0.250
+7.84 %
20 Days --0.740
-17.70 %
Medium Term Return 3 Months --7.630
-68.93 %
6 Months --16.430
-82.69 %
1 Year --14.565
-80.89 %
Long Term Return 2 Years --73.190
-95.51 %
3 Years --27.180
-88.77 %
5 Years --55.610
-94.17 %
Annualised Return Annualised --
-43.37 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 3.010 - 32.050 Change From 1 Year Low +0.430 % Change From 1 Year Low (%) +14.29
Change From 1 Year High -28.610 % Change From 1 Year High (%) -89.27
2 Years Range 3.010 - 78.430 Change From 2 Years Low +0.430 % Change From 2 Years Low (%) +14.29
Change From 2 Years High -74.990 % Change From 2 Years High (%) -95.61
5 Years Range 3.010 - 116.750 Change From 5 Years Low +0.430 % Change From 5 Years Low (%) +14.29
Change From 5 Years High -113.310 % Change From 5 Years High (%) -97.05
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Oct 2019 3.500 3.600 3.380 3.440 2,498,564 -
21 Oct 2019 3.360 3.600 3.310 3.440 1,645,113 -
18 Oct 2019 3.700 3.750 3.290 3.340 3,354,238 -
17 Oct 2019 3.260 3.760 3.210 3.660 3,893,503 -
16 Oct 2019 3.230 3.320 3.190 3.200 1,857,922 -
15 Oct 2019 3.110 3.330 3.010 3.205 4,081,936 -
14 Oct 2019 3.300 3.360 3.110 3.120 2,080,853 -
11 Oct 2019 3.210 3.370 3.170 3.275 3,160,975 -
10 Oct 2019 3.220 3.395 3.120 3.170 3,589,083 -
09 Oct 2019 3.180 3.270 3.130 3.190 4,354,846 -
08 Oct 2019 3.500 3.550 3.140 3.160 4,154,429 -
07 Oct 2019 3.700 3.710 3.570 3.600 2,340,801 -
04 Oct 2019 3.850 3.885 3.700 3.710 2,104,919 -
03 Oct 2019 4.020 4.077 3.740 3.855 2,981,105 -
02 Oct 2019 3.950 4.130 3.700 4.050 2,722,332 -
01 Oct 2019 3.910 4.220 3.830 4.000 2,810,279 -
30 Sep 2019 4.090 4.130 3.760 3.930 4,079,734 -
27 Sep 2019 4.020 4.330 3.970 4.000 4,318,070 -
26 Sep 2019 4.160 4.240 4.000 4.010 2,405,976 -
25 Sep 2019 4.270 4.430 4.080 4.180 2,696,415 -
24 Sep 2019 4.450 4.450 3.970 4.270 6,222,570 -
23 Sep 2019 4.760 4.870 4.560 4.585 3,364,475 -
Summary
Current 2 Weeks
(09 Oct 2019 to 22 Oct 2019)
3.180 3.760 3.010 3.440 30,517,033 -
Previous 2 Weeks
(25 Sep 2019 to 08 Oct 2019)
4.270 4.430 3.010 3.160 30,614,060 -
4 Weeks from
(27 Aug 2019 to 24 Sep 2019)
6.090 6.160 3.010 4.270 78,798,279 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.